Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02570321 · ClinicalTrials.gov registry record · Phase 3
Cross-linking for Corneal Ulcers Treatment Trial
A Phase 3 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 3
- Development phase
- 147
- Enrollment target
NCT02570321: Completed Phase 3 study, sponsored by University of California, San Francisco.
NCT02570321 is a Phase 3 study that has completed, run by University of California, San Francisco. The registered enrollment target is 147 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02570321, a Phase 3 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 147 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine if patients randomized to corneal collagen cross-linking plus medical therapy will have a lower prevalence of positive bacterial or fungal cultures immediately after the procedure than patients who received medical therapy alone. The secondary purpose of this study is to determine if patients randomized to corneal collagen cross-linking will have a better visual acuity at 3 and 12 months than patients who receive medical therapy alone.
Primary Outcome
Corneal scraping of the ulcer will be performed and directly inoculated on to sheep's blood agar, chocolate agar, potato dextrose agar or Sabouraud's agar for bacterial and fungal culture. Microbiological cure is defined as no growth of bacteria or fungus on these media.
Interventions
- PROCEDURE Corneal Cross-linking
- DRUG Anti Fungal Drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2015-11 |
| Est. Completion | 2019-03-19 |
| Phase | Phase 3 |
What the finished NCT02570321 record still lists
NCT02570321 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Corneal Cross-linking is the first listed.
NCT02570321 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02570321 about?
NCT02570321 is a clinical study titled "Cross-linking for Corneal Ulcers Treatment Trial". The primary purpose of this study is to determine if patients randomized to corneal collagen cross-linking plus medical therapy will have a lower prevalence of positive bacterial or fungal cultures immediately after the procedure than patients who received medical therapy alone. The secondary purpo...
What is the current status of trial NCT02570321?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 147 participants. The study started on 2015-11. Estimated completion is 2019-03-19.
What interventions are being tested in trial NCT02570321?
The interventions under investigation include: Corneal Cross-linking (PROCEDURE), Anti Fungal Drug (DRUG).
Who is sponsoring clinical trial NCT02570321?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02570321's enrollment target sits among peer trials
147 1550th of 2000 higher than 450 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia